Search companies

Live

ANTEOTECH LTD (ASX: ADO)

Health care · News and insights

Price unavailable

Latest ADO announcements

Announcement Insights

AnteoTech Revenue Halves as Sales Conversion Becomes Priority

AnteoTech’s FY2026 revenue fell to about $468,000 from about $969,000, prompting management to make converting its customer pipeline into sales the company’s top priority. The decline was partly attributed to a Serum Institute shipment moving into July; the company reported cash expenses down 19% and finished the year with $11 million in cash and no debt, while battery and diagnostics evaluations continued.

Updated 16 Nov 2026, 03:55 PM Sydney time
Share
SourcesNotification of cessation of securities - ADONotification regarding unquoted securities - ADOChange of Director's Interest Notice x 3Application for quotation of securities - ADOChair's Address to ShareholdersManaging Director AGM PresentationResults of MeetingQuarterly Activities/Appendix 4C Cash Flow ReportAppointment of CFO and Company Secretary
Comments

AnteoTech Issues Director Incentive Shares And Options

2026-11-12 · Health care

ADO: $0.017 +0.00% · MC: $56M

AnteoTech issued its managing director 2.3 million shares under the FY2026 incentive plan and granted long-term options to its CEO and directors, following shareholder approval at the AGM. The shares were issued for no cash consideration, and the options are exercisable at 3.75 cents through November 2030.

Updated 2026-11-12 10:13
Share
SourcesNotification regarding unquoted securities - ADOChange of Director's Interest Notice x 3
Comments

AnteoTech Flags Sales Conversion As Key Task After Revenue Falls

2026-11-10 · Health care

ADO: $0.017 +6.25% · MC: $56M

At its 2026 AGM, AnteoTech said converting its customer pipeline into sales is its top priority after FY2026 revenue fell to about $468,000 from about $969,000, partly because a Serum Institute shipment shifted into July. The company reported cash expenses down 19% and ended the year with $11 million in cash and no debt; it also highlighted battery and diagnostics progress, including Ultranode 95 testing and ongoing customer evaluations. All AGM resolutions were passed.

Updated 2026-11-10 17:09
Share
SourcesChair's Address to ShareholdersManaging Director AGM PresentationResults of Meeting
Comments

AnteoTech Advances Battery and Diagnostics Deals, Ends Quarter With $11 Million Cash

2026-10-29 · Health care

ADO: $0.016 +14.29% · MC: $56M

AnteoTech reported expanded customer evaluations and commercial activity across its battery and life sciences businesses, including agreements with Xerabrid and Airspeeder and progress on a collaboration with a global life sciences company. It received approximately $2 million in research and development tax incentives and ended the quarter with $11 million in cash and cash equivalents, including $5.5 million on term deposit, with no bank debt. The excerpt does not provide a prior-quarter cash figure for comparison.

Updated 2026-10-29 09:37
Share
SourcesQuarterly Activities/Appendix 4C Cash Flow Report
Comments